Pediatric Primary Anaplastic Ganglioglioma: A Case Report and Review of the Literature (original) (raw)
Article navigation
Case Reports| August 21 2012
aRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, and
Search for other works by this author on:
aRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, and
Search for other works by this author on:
aRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, and
Search for other works by this author on:
aRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, and
Search for other works by this author on:
aRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, and
Search for other works by this author on:
aRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, and
Search for other works by this author on:
cPediatric OncoHematology Unit and
Search for other works by this author on:
dPathology Unit, Anna Meyer Children’s Hospital, Florence, Italy
Search for other works by this author on:
cPediatric OncoHematology Unit and
Search for other works by this author on:
aRadiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, and
Search for other works by this author on:
Pediatr Neurosurg (2012) 48 (1): 35–41.
Citation
Silvia Scoccianti, Flavio Giordano, Benedetta Agresti, Beatrice Detti, Samantha Cipressi, Davide Franceschini, Daniela Greto, Federico Mussa, Iacopo Sardi, Annamaria Buccoliero, Maurizio Aricò, Lorenzo Genitori, Giampaolo Biti; Pediatric Primary Anaplastic Ganglioglioma: A Case Report and Review of the Literature. _Pediatr Neurosurg 1 October 2012; 48 (1): 35–41. https://doi.org/10.1159/000340067
Download citation file:
Abstract
Gangliogliomas with anaplastic features are classified as grade III tumors by the World Health Organization. The clinical course and optimal treatment of anaplastic gangliogliomas have not been well understood to date. We report a case of a primary pure anaplastic ganglioglioma in a 14-year-old male treated with surgery and radiotherapy, who is disease-free 6 years after the diagnosis. A review of primary pure anaplastic gangliogliomas in children (between 3 and 21 years of age) is presented. Gross total removal and focal radiotherapy with a total dose of 54 Gy are recommended. The addition of chemotherapy should be evaluated. Prospective studies are needed to identify an appropriate chemotherapy schedule and to define biological factors in order to select those patients with a poor prognosis, who are to be treated with a more aggressive therapy.
References
Spennato P, Giordano M, Ruggiero C, Aliberti F, Buonocore MC, Nastro A, D’Onofrio V, Bifani D, Cinalli G: Optic pathway ganglioglioma with intraventricular cyst. J Neurooncol 2011;102:499–508.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO Classication of Tumours of the Central Nervous System. Acta Neuropathol 2007;114:97–109.
Luyken C, Blumcke I, Fimmers R, Urbach H, Wiestler OD, Schramm J: Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer 2004;101:146–155.
Isimbaldi G, Sironi M, Tonnarelli GP, Roncoroni M, Declich P, Galli C: Ganglioglioma: a clinical and pathological study of 12 cases. Clin Neuropathol 1996;15:192–199.
DeMarchi R, Abu-Abed S, Munoz D, Loch Macdonald R: Malignant ganglioglioma: case report and review of literature. J Neurooncol 2011;10:311–318.
Karremann M, Pietsch T, Janssen G, Kramm CM, Wolff JE: Anaplastic ganglioglioma in children. J Neurooncol 2009;92:157–163.
Blümcke I, Wiestler OD: Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol 2002;61:575–584.
Rades D, Zwick L, Leppert J, Bonsanto MM, Tronnier V, Dunst J, Schild SE: The role of postoperative radiotherapy for the treatment of gangliogliomas. Cancer 2010;116:432–442.
Kang DH, Lee CH, Hwang SH, Park IS, Han JW, Jung JM: Anaplastic ganglioglioma in a middle-aged woman: a case report with a review of the literature. J Korean Med Sci 2007;22:S139–S144.
Kawataki T, Sato E, Sato T, Kinouchi H: Anaplastic ganglioglioma with malignant features in both neuronal and glial components. Neurol Med Chir 2010;50:228–231.
Mittelbronn M, Schittenhelm J, Lemke D, Ritz R, Nägele T, Weller M, Meyermann R, Beschorner R: Low grade ganglioglioma rapidly progressing to a WHO grade IV tumor showing malignant transformation in both astroglial and neuronal cell components. Neuropathology 2007;27:463–467.
Hirose T, Kannuki S, Nishida K, Matsumoto K, Sano T, Hizawa K: Anaplastic ganglioglioma of the brain stem demonstrating active neurosecretory features of neoplastic neuronal cells. Acta Neuropathol 1992;83:365–370.
Nakajima M, Kidooka M, Nakasu S: Anaplastic ganglioglioma with dissemination to the spinal cord: a case report. Surg Neurol 1998;49:445–448.
Tarnaris A, O’Brien C, Redfern RM: Ganglioglioma with anaplastic recurrence of the neuronal element following radiotherapy. Clin Neurol Neurosurg 2006;108:761–767.
Zorlu F, Selek U, Onal C, Söylemezoğlu F, Gurkaynak M: Postoperative radiotherapy in cranial ganglioglioma. J Neurooncol 2006;77:321–324.
Pandita A, Balasubramaniam A, Perrin R, Shannon P, Guha A: Malignant and benign ganglioglioma: a pathological and molecular study. Neuro Oncol 2007;9:124–134.
Rumana CS, Valadka AB: Radiation therapy and malignant degeneration of benign supratentorial gangliogliomas. Neurosurgery 1998;42:1038–1043.
Im SH, Chung CK, Cho BK, Wang KC, Yu IK, Song IC, Cheon GJ, Lee DS, Kim NR, Chi JG: Intracranial ganglioglioma: preoperative characteristics and oncologic outcome after surgery. J Neurooncol 2002;59:173–183.
Kurian NI, Nair S, Radhakrishnan VV: Anaplastic ganglioglioma: case report and review of the literature. Br J Neurosurg 1998;12:277–280.
Selch MT, Goy BW, Lee SP: Gangliogliomas: experience with 34 patients and review of the literature. Am J Clin Oncol 1998;21:557–564.
Liauw SL, Byer JE, Yachnis AT, Amdur RJ, Mendenhall WM: Radiotherapy after subtotally resected or recurrent ganglioglioma. Int J Radiat Oncol Biol Phys 2007;67:244–247.
Campos MG, Zentner J, Ostertun B, Wolf HK, Schramm J: Anaplastic ganglioglioma: case report and review of the literature. Neurol Res 1994;16:317–320.
Zentner J, Wolf HK, Ostertun B, Hufnagel A, Campos MG, Solymosi L, Schramm J: Gangliogliomas: clinical, radiological and histopathological findings in 51 patients. J Neurol Neurosurg Psychiatry 1994;57:1497–1502.
Silver JM, Rawlings CE 3rd, Rossitch E Jr, Zeidman SM, Friedman AH: Ganglioglioma: a clinical study with long-term follow-up. Surg Neurol 1991;35:261–266.
Chintagumpala MM, Armstrong D, Miki S, Nelson T, Cheek W, Laurent J, Woo SY, Mahoney DH: Mixed neuronal-glial tumors (gangliogliomas) in children. Pediatr Neurosurg 1996;24:306–313.
Haddad SF, Moore SA, Menezes Ah, VanGilder JC: Ganglioglioma: 13 years of experience. Neurosurgery 1992;31:171–178.
Rodewald L, Miller DC, Sciorra L, Barabas G, Lee ML: Central nervous system neoplasm in a young man with Martin-Bell syndrome – fra(X)-XLMR. Am J Med Genet 1987;26:7–12.
Wagner S, Reinert C, Schmid HJ, Liebeskind AK, Jorch N, Graf N, Warmuth-Metz M Pietsch T, Peters O, Wolff JE: High-dose methotrexate prior to simultaneous radiochemotherapy in children with malignant high-grade gliomas. Anticancer Res 2005;25:2583–2588.
Matsuzaki K, Uno M, Kageji T, Hirose T, Nagahiro S: Anaplastic ganglioglioma of the cerebellopontine angle. Neurol Med Chir 2005;45:591–595.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
Sign in
Digital Version
Pay-Per-View Access
$39.00
1 Karger Article Bundle Token
$150
Rental
This article is also available for rental through DeepDyve. 